Shalby Limited has formally communicated to stock exchanges that it does not fall under the 'Large Corporate' category as defined by SEBI regulations, exempting the company from specific compliance requirements for the year ended March 31, 2026.

Regulatory Compliance Notification

Through a regulatory filing dated April 15, 2026, the healthcare company notified both the National Stock Exchange of India and BSE Limited about its non-applicability status under SEBI's Large Corporate criteria. The notification was signed by Tushar Shah, AVP & Company Secretary, and submitted through the respective exchange platforms.

SEBI Circular Compliance Framework

The company's confirmation is based on compliance with two key SEBI circulars governing fund raising through debt securities by large entities. The regulatory framework establishes specific criteria that determine whether a company qualifies as a 'Large Corporate' entity.

Exemption from Annual Disclosure Requirements

Since Shalby Limited does not fulfill the applicability criteria specified in Para 3.2 of the aforementioned SEBI circulars, the company is exempt from the annual disclosure requirements typically mandated for Large Corporate entities. This exemption specifically relates to disclosures required for fund raising through issuance of debt securities.

The notification serves as an official confirmation to stock exchanges and regulatory authorities, ensuring proper compliance documentation and maintaining transparency in corporate governance practices. The company has requested both exchanges to record this confirmation in their official records.

Shalby Limited has received regulatory approval for kidney transplant services at its Krishna unit in Ahmedabad, Gujarat, marking a significant expansion of the company's healthcare capabilities. The approval, effective from April 9, 2026, grants the facility authorization to conduct kidney transplant procedures for a period of five years.

Regulatory Approval Details

The healthcare provider informed stock exchanges about this development through a regulatory filing under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The approval specifically covers kidney transplant operations at Shalby Hospitals' Krishna unit located in Ahmedabad.

Healthcare Impact and Benefits

The company emphasized that this approval will significantly benefit patients in the surrounding community by providing local access to advanced, life-saving transplant services. The development addresses a critical healthcare need by eliminating the necessity for patients to travel long distances for kidney transplant procedures, thereby reducing associated costs and logistical challenges.

Shalby Limited highlighted that the approval enhances continuity of care by enabling the facility to offer comprehensive pre- and post-transplant management services under one roof. This integrated approach ensures patients receive complete care throughout their transplant journey at a single location.

Strategic Significance

The kidney transplant approval represents a notable milestone for Shalby Limited's Krishna unit, expanding its specialized medical services portfolio. The five-year authorization period provides the facility with substantial operational runway to establish and develop its transplant program while serving the healthcare needs of the Gujarat region.

The company's ability to secure this approval demonstrates its commitment to providing advanced medical services and expanding access to critical healthcare procedures in the region.